« FDA Approvals - Minnesota lawmakers critique FDA medical devices policy over IDEsThe medical | Main | FDA approves Nulojix for kidney transplant patients The U.S. Food »

CytRx Receives FDA Orphan Drug Designation for INNO-206 for the


CytRx Receives FDA Orphan Drug Designation for INNO-206 for the Treatment of Soft Tissue Sarcomas
CytRx Corporation , a biotechnology company specializing in oncology, today announced that the Office of Orphan Product Development of the U.S. Food and Drug Administration has granted INNO-206 orphan drug designation for the treatment of patients with soft tissue sarcomas.

FDA warns sprout farm; experts say defeating bacteria can be a tough task
To sprout shoots, seeds need a warm, moist environment. Problem is, bacteria like E. coli and salmonella also happen to love that kind of setting. read more
 

©2006 FDA-News.com. All rights reserved.